---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-036510"
form_type: "8-K"
ticker: "ZVSA"
cik: "0001859007"
company_name: "ZyVersa Therapeutics, Inc."
filed_at: "2022-12-23T23:59:59+00:00"
generated_at: "2026-06-20T23:40:50.816698+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# ZyVersa extends waiver of $1.5M milestone payments due to L&F Research to March 31, 2023

## Summary
- Second Amendment to Waiver extends L&F Research's forbearance on terminating license for non-payment of $500K IND Milestone and two $500K Phase 1/2 milestone payments.
- Waiver Period extended to March 31, 2023; original deadline was January 3, 2023.
- If license is terminated for other reasons or a bankruptcy event occurs before July 31, 2023, the waiver is void and payment obligations retroactively reinstated.
- All other terms of the underlying License Agreement remain unchanged.

## SEC filing metadata
- accession: 0001493152-22-036510
- form_type: 8-K
- ticker: ZVSA
- cik: 0001859007
- company_name: ZyVersa Therapeutics, Inc.
- filed_at: 2022-12-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1859007/000149315222036510/0001493152-22-036510-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1859007/000149315222036510/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-036510
- JSON: https://secwatch.observer/filing/0001493152-22-036510.json
- Plain text: https://secwatch.observer/filing/0001493152-22-036510.txt

## Key facts
- Material Agreements
  ZyVersa Therapeutics, Inc. amended Second Amendment to Waiver of Certain Rights under License Agreement with L&F Research LLC valued at $1,500,000 (effective 2022-12-23).
  - Action: amendment
  - Agreement: license
  - Counterparty: L&F Research LLC
  - Value: $1,500,000
  - Effective: 2022-12-23
  source text: On December 23, 2022, ZyVersa Therapeutics, Inc., a Delaware corporation (the “Company”) entered into a Second Amendment to Waiver of Certain Rights under License Agreement, by and between L&F Research and ZyVersa Therapeutics, Inc., a Florida corporation (“Old ZyVersa”), a wholly owned subsidiary of the Company (the “Second Amendment”), amending the previously disclosed Waiver Agreement, dated March 2, 2022, by and between L&F Research and Old ZyVersa (the “Waiver Agreement”), as amended.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1859007/000149315222036510/0001493152-22-036510-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.